Alzheimers & dementia-translational research & clinical interventions文章索引

A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study [0.03%] 阿尔茨海默病认知和功能进展的综合衡量指标：开展认知变化调查研究

Roos J Jutten,John Harrison,Frank Jan de Jong et al. Roos J Jutten et al.

Introduction: Cognitive testing in Alzheimer's disease (AD) is essential for establishing diagnosis, monitoring progression, and evaluating treatments. Assessments should ideally be brief, reliable, valid, and reflect cli...

Alzheimer's & dementia (New York, N. Y.). 2017 Feb 9;3(1):130-138. DOI:10.1016/j.trci.2017.01.004 2017

Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients [0.03%] 间断性缺氧/富氧训练对老年患者认知功能的影响

Urike Bayer,Rudolf Likar,Georg Pinter et al. Urike Bayer et al.

Introduction: Intermittent hypoxic-hyperoxic training (IHHT) may complement a multimodal training intervention (MTI) for improving cognitive function and exercise tolerance in geriatric patients. ...

Alzheimer's & dementia (New York, N. Y.). 2017 Feb 8;3(1):114-122. DOI:10.1016/j.trci.2017.01.002 2017

The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database [0.03%] ADNI数据库中快速进展型阿尔茨海默病的流行特征及生物标志物研究

Maowen Ba,Xiaofeng Li,Kok Pin Ng et al. Maowen Ba et al.

Introduction: The prevalence and detailed biomarkers' characteristic of rapidly progressive Alzheimer's disease (rpAD) remain incompletely understood. Met...

Alzheimer's & dementia (New York, N. Y.). 2017 Feb 9;3(1):107-113. DOI:10.1016/j.trci.2016.12.005 2017

Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease [0.03%] 利普汀和吡格列酮联合治疗阿兹海默病小鼠模型的效果研究

Carmen M Fernandez-Martos,Rachel A K Atkinson,Meng I Chuah et al. Carmen M Fernandez-Martos et al.

Introduction: Combination therapy approaches may be necessary to address the many facets of pathologic change in the brain in Alzheimer's disease (AD). The drugs leptin and pioglitazone have previously been shown individu...

Alzheimer's & dementia (New York, N. Y.). 2016 Dec 20;3(1):92-106. DOI:10.1016/j.trci.2016.11.002 2016

Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development [0.03%] 阿尔茨海默病病理改变共存的多重共病性神经病理及其对药物研发的影响

Gil D Rabinovici,Maria C Carrillo,Mark Forman et al. Gil D Rabinovici et al.

Dementia is often characterized as being caused by one of several major diseases, such as Alzheimer's disease (AD), cerebrovascular disease, Lewy body disease, or a frontotemporal degeneration. Failure to acknowledge that more than one enti...

Review Alzheimer's & dementia (New York, N. Y.). 2016 Sep 20;3(1):83-91. DOI:10.1016/j.trci.2016.09.002 2016

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials [0.03%] 非洲裔美国人较少参加阿尔茨海默病前期临床试验

Yan Zhou,David Elashoff,Sarah Kremen et al. Yan Zhou et al.

Introduction: Alzheimer's disease (AD) incidence is disproportionately high in African Americans, yet, recruitment of this community to AD clinical trials is challenging. ...

Alzheimer's & dementia (New York, N. Y.). 2016 Oct 15;3(1):57-64. DOI:10.1016/j.trci.2016.09.004 2016

Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease [0.03%] 新型胰岛素受体拮抗剂AC253改善阿尔茨海默病小鼠模型的认知缺陷

Rania Soudy,Aarti Patel,Wen Fu et al. Rania Soudy et al.

Introduction: Amylin receptor serves as a portal for the expression of deleterious effects of amyloid β-protein (Aβ), a key pathologic hallmark of Alzheimer's disease. Previously, we showed that AC253, an amylin recepto...

Alzheimer's & dementia (New York, N. Y.). 2016 Dec 10;3(1):44-56. DOI:10.1016/j.trci.2016.11.005 2016

Social interaction and cognitive decline: Results of a 7-year community intervention [0.03%] 社会交往与认知衰退：一项为期七年的社区干预结果

Hiroyuki Hikichi,Katsunori Kondo,Tokunori Takeda et al. Hiroyuki Hikichi et al.

Introduction: There are few intervention studies that demonstrated linking social participation to lower risk of cognitive decline. We examined prospectively the protective effect of a community intervention program promo...

Alzheimer's & dementia (New York, N. Y.). 2016 Dec 21;3(1):23-32. DOI:10.1016/j.trci.2016.11.003 2016

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study [0.03%] 阿尔茨海默病治疗性主动Aβ免疫疗法CAD106的二期临床试验研究

Rik Vandenberghe,Marie-Emmanuelle Riviere,Angelika Caputo et al. Rik Vandenberghe et al.

Introduction: This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity of CAD106 with/without adjuvant in patients with mild Alzheimer's disease. ...

Alzheimer's & dementia (New York, N. Y.). 2016 Dec 23;3(1):10-22. DOI:10.1016/j.trci.2016.12.003 2016

Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease [0.03%] ORM-12741的耐受性和对阿尔茨海默病患者情节记忆的影响

Juha O Rinne,Keith Wesnes,Jeffrey L Cummings et al. Juha O Rinne et al.

Introduction: ORM-12741 is a novel selective antagonist of alpha-2C adrenoceptors. This trial evaluated the safety and efficacy of ORM-12741 in patients with Alzheimer's disease (AD). ...

Alzheimer's & dementia (New York, N. Y.). 2016 Dec 8;3(1):1-9. DOI:10.1016/j.trci.2016.11.004 2016